53 results about "Carcinoembryonic Antigen Positive" patented technology

The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.

The present invention provides for methods for immunizing actively against autologous carcinoembryonic antigen (CEA). The method encompasses that the immune system is engaged with variant CEA which is either administered as a protein vaccine, or is effected expressed by nucleic acid vaccination or live-viral vaccination. Preferred embodiments include immunization with variants that include at least one foreign T-helper epitope introduced in the CEA sequence. Also disclosed is variant proteins, DNA, vectors, and host cells useful for practising the method of the invention.

A fusion protein CEA-Hsp70L1 of human carcino-embryonic antigen and heat shock protein 70L1, the DNA sequence for coding it, the carrier containing the DNA sequence, the host cell containing said carrier, the process for preparing said fusion protein by genetic engineering, and the composition containing the fusion protein are disclosed. A process for preparing the therapeutic vaccine of CEA positive cancer is also disclosed.

The invention discloses a high-affinity anti-carcinoembryonic antigen nanobody. The nanobody has three unique complementary determining regions CDR1, CDR2 and CDR3. The invention further provides an expression vector containing a nanobody variable region coding sequence and a host cell containing the expression vector, and further provides fusion protein of a nanobody variable region and alkalinephosphatase, the application of the nanobody to preparation of a carcinoembryonic antigen detection kit, a method for performing immunodetection on a carcinoembryonic antigen by applying the nanobody,and the corresponding detection kit. The anti-carcinoembryonic antigen (CEA) nanobody provided by the invention has a specific CEA recognizing and bonding ability, has the affinity which can reach 4.791E-10, and has unique antigen-determining cluster recognition sites; an excellent detection result can be obtained in CEA immunodetection, especially in a double-antibody sandwich method.

The invention discloses an electrochemiluminescence method for detecting a carcinoembryonic antigen and a kit thereof. The method adopts the carcinoembryonic antigen as a detection object, organicallycombines a high quantum yield gold nanocluster electrochemiluminescence technology and an immunoassay technology, adopts a reduction method to prepare a high quantum yield gold nanocluster electrochemiluminescence probe, and uses a manganese dioxide nanomaterial as an electrochemiluminescence quencher to recover an electrochemiluminescence signal by an oxidation-reduction reaction of manganese dioxide and ascorbic acid produced by an enzyme-linked immunosorbent reaction, thereby developing the novel high-performance electrochemiluminescence carcinoembryonic antigen detection method based on high quantum yield gold nanocluster probes and the detection kit. The linear range of detection of a carcinoembryonic antigen in the method is 3*10-5 ng/mL-3 ng/mL, and the detection limit is 27 fg/mL.The method has the advantages of being fast, accurate, high in sensitivity, good in selectivity and stability, low in sample consumption and the like, and has a good clinical application prospect.

The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.

This invention belongs to anti-carcinoe mbryonic antigen recombination immuno toxin. It is concretely relates to said antigen immuno toxic with (Arg)9 based on pseudomonic extotoxin. Nucleuotide sequence code-connects ectotoxin and the antigen connecting peptide, contains the expressing carrier of the sequence and the xeno-cell of the sequence and the utilization of the prevention and cure of tumor.

The aim of the invention is to provide a carcinoembryonic antigen (CEA) rapid simple detection kit and making and application methods thereof, the carcino-embryonic antigen rapid simple detection kit is lower in cost than a test strip; by use of specific responses of human carcinoembryonic antigen and anti carcinoembryonic antigen antibody, the carcinoembryonic antigen and the antibody are bonded onto a NC (nitrocellulose) membrane and colloidal gold particles, a colloidal gold and antibody complex is added onto the NC membrane, and whether the CEA is negative or positive is determined by observation of the color. When the CEA content is lower than 2.5uM, a 2.5uM CEA standard product is not significantly different from a 0uM standard product in color development, so when the CEA content is lower than 2.5uM, the CEA is determined to be negative; when the CEA content is in the 2.5-10uM range, the detection point color is significantly shallower than the 0uM spot color, the CEA is determined to be weak positive; when the CEA content is more than 10uM, and no red spot appears, the CEA is determined to be positive.

The invention provides a CEA resisting antibody. The CEA resisting antibody comprises a heavy chain variable region and a light chain variable region, wherein the complementary determining region of the heavy chain variable region comprises CDR-H1 of which the amino acid sequence is shown as SEQID No.1, CDR-H2 of which the amino acid sequence is shown as SEQID No.2 and CDR-H3 of which the amino acid sequence is shown as SEQID No.3, and the complementary determining region of the light chain variable region comprises CDR-L1 of which the amino acid sequence is shown as SEQID No.4, CDR-L2 of which the amino acid sequence is shown as SEQID No.5 and CDR-L3 of which the amino acid sequence is shown as SEQID No.6. The inventor uses a phage display technique to screen CEA scFv, so as to obtain a high-affinity CEA resisting single-chain antibody. The chimeric antigen receptor gene for resisting CEA is transmitted into T cells by a genetic engineering method to prepare CEA CAR-T, so that the digestive tract tumor cells of CEA can be specially recognized and expressed by CEA CAR-T cells, and are killed, and the effect of resisting tumors can be realized.

The invention belongs to biotechnologies and relates to regulation and control of gene expression, in particular to design and preparation of a targeted gene expression element CPD specifically aimingat a carcinoembryonic antigen positive tumor cell and specific expression in the carcinoembryonic antigen positive tumor cell. A product can effectively block DNA replication in the tumor cell so that a cell cycle can not be carried out due to the blockage of the DNA replication, and the effect of inhibiting cell proliferation can be achieved. The invention can be used for preparing a targeted tumor gene treating medicine. The invention has the advantages of favorable tumor inhibiting effect, wide adaptability and high safety.

The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.

The invention discloses a tumor gene diagnosis marker combined with carcinoembryonic antigen and application of the tumor gene diagnosis marker. By combining miR-609 and the carcinoembryonic antigen, the colorectal cancer screening accuracy is improved, and the defect that the accuracy is not high when the carcinoembryonic antigen is independently used for colorectal cancer screening is overcome. Therefore, the miR-609 can be combined with the carcinoembryonic antigen to prepare a serum detection kit for early diagnosis of colorectal cancer.

The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of cancer, preferably colorectal cancer (CRC), in a subject. The method is based on the determination of the level of a panel of least one, preferably 3, 4 and most preferably at least 5, protein biomarker selected from the group consisting of the protein biomarkers Amphiregulin (AREG), Carcinoembryonic antigen (CEA), Insulin like growth factor binding protein 2 (IGFBP2), Keratin, type I cytoskeletal 19 (KRT19), Mannan binding lectin serine protease 1 (MASP1), Osteopontin (OPN), Serum paraoxonase lactonase 3 (PON3) and Transferrin receptor protein 1 (TR), in the biological sample obtained from the subject. The new biomarker panel of the invention allows diagnosing and even stratifying various cancer diseases. Furthermore, provided are diagnostic kits for performing the non-invasive methods of the invention. Since the biomarker panel of the invention provides a statistically robust method independent of the protein detection technology used, and considering that the biomarker panel of the invention is detected in plasma samples of the subjects, the invention provides an early detection screening examination that may be applied to a larger population.

The invention relates to a method for detecting a cell capable of expressing a carcinoembryonic antigen, and application thereof. A bacteriophage display technology is used for displaying a single chain antibody capable of resisting the carcinoembryonic antigen on the surface of auxiliary bacteriophage M13KO7 to construct a library of the single chain antibody capable of resisting the carcinoembryonic antigen. The library is used as a probe, the cell capable of expressing the carcinoembryonic antigen is subjected to specific targeted combination, and then, a magnetic nanoparticle modified by an antibody capable of resisting the carcinoembryonic antigen is used for capturing the category of cells. Through PCR (Polymerase Chain Reaction), the g3p gene of M13KO7 is amplified so as to achievea purpose of quickly and sensitively detecting the single cell capable of expressing the carcinoembryonic antigen or low-content circulating tumor cells.

The present invention relates to a CEA gene vaccine, its construction method and application in preparation of vaccine for preventing and curing tumor. It is characterized by that it utilizes eukaryotic cell expression plasmid to construct the carcion-embryonic antigen (CEA) gene vaccine with interleukin 2 coordinate expression. The detection shows that in the external cell it can implement coordinate expression of CEA and IL-2 protein molecule, and the animal model tests show that the CEA gene vaccine has the action of preventing and curing carcion-embryonic antigen positive tumor, and in the body it has not immunotoxic effect.

The invention provides a preparation method of a hydrogel preparation based on quantum dots and gold nanorods. The preparation method comprises the following steps of firstly, combining the quantum dots with a carcinoembryonic antigen aptamer; secondly, combining the gold nanorods with the carcinoembryonic antigen aptamer; thirdly, mixing the quantum dots modified by the carcinoembryonic antigen aptamer, the gold nanorods modified by the carcinoembryonic antigen aptamer and a hydrogel solution; and finally, obtaining the hydrogel preparation based on the quantum dots and the gold nanorods. Theprepared hydrogel preparation can be used for detecting a carcinoembryonic antigen, and when the hydrogel preparation is co-incubated with the carcinoembryonic antigen whose concentration of 1-6 microliters is 1 mg/ml, the light quenching efficiency is 12-24%.

The invention discloses application of blood platelet membrane protein in the diagnosis of acute coronary syndrome. The blood platelet membrane protein is a protein-carcinoembryonic antigenelated celladhesion molecule 5(CEACAM5/CEA) that was first discovered by an inventor to be expressed on blood platelet membrane. According to the blood platelet membrane surface CEA level, patients with the acute coronary syndrome and patients with normal coronary arteries are diagnosed and distinguished, the area under the curve(AUC) of the receiver operating characteristic curve(ROC) is 0.86, and clinicaldiagnostic significance is achieved; and when troponin(cTnI) is combined for diagnosis, the AUC reaches 0.91. The blood platelet membrane protein can be used for diagnosis of the acute coronary syndrome, the sensitivity is high, and the specificity is high.